⟵ Back to Search Results

AdvanTIG-204

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Beigene Study ID info

AdvanTIG-204

ClinicalTrials.gov ID info

NCT04952597

China Drug Trials ID info

CTR20211531

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan